Suven Life Sciences hosting analyst meet on 17 Jul 2026

0 min read Updated on 16 Jul 2026, 12:53 AM

Reviewed by

Shriram SScanX News Team

AI Summary

Suven Life Sciences Limited has scheduled an interaction with investors and analysts on July 17, 2026, in Mumbai. The meeting will provide a platform for the management to engage with the investor community through both group and one-on-one sessions. The company confirmed that no unpublished price-sensitive information will be shared during this interaction.

*this image is generated using AI for illustrative purposes only.

Suven Life Sciences Limited will host an interaction with investors and analysts on July 17, 2026, in Mumbai. The management will engage with the investor community through both group and one-on-one sessions. The company confirmed that no unpublished price-sensitive information will be shared during this interaction.

The meeting details were communicated to the stock exchanges pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The schedule for the interaction is subject to change by the investors or the company.

Date	Conference	Place	Group/one-one	Mode
17-07-2026	Interaction with Investors & Analysts	Mumbai	Group/One-one	In-person

The intimation was signed by K. Sangeetha Laxmi, Company Secretary and Compliance Officer of Suven Life Sciences Limited.

Historical Stock Returns for Suven Life Sciences

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.86%	-0.58%	-5.42%	+108.53%	+15.27%	+237.71%

What key strategic priorities is Suven Life Sciences likely to emphasize during the investor interaction?

How might the outcomes of this meeting influence investor sentiment ahead of the company's next earnings report?

Could this interaction signal any upcoming shifts in Suven Life Sciences' business model or market focus?

Read Next Article

Suven Life Sciences to Present Five Scientific Posters at AAIC 2026

1 min read Updated on 10 Jul 2026, 12:46 PM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

AI Summary

Suven Life Sciences will present five scientific posters at the Alzheimer's Association International Conference (AAIC) 2026, scheduled from July 12 to July 15 in London, covering updates on its global Phase-3 Masupirdine program for Alzheimer's-related agitation and the Usmarapride Phase-2 clinical development program. The company holds five clinical-stage CNS assets and plans to explore strategic partnering opportunities at the event.

*this image is generated using AI for illustrative purposes only.

Suven Life Sciences will present five scientific posters at the Alzheimer's Association International Conference (AAIC) 2026, including updates on its global Phase-3 Masupirdine clinical program for agitation associated with Alzheimer's Dementia and the Usmarapride Phase-2 clinical development program. The conference is scheduled from July 12 to July 15, 2026, in London, United Kingdom. The presentations will provide insights into the study population and trial progress for Masupirdine, alongside broader non-clinical and clinical research advances across the company's neuroscience pipeline.

The AAIC serves as the largest international conference dedicated to advancing dementia science and clinical practice. Suven Life Sciences aims to engage with investigators, key opinion leaders, and the global research community during the event. The company also plans to explore strategic partnering opportunities for its clinical-stage central nervous system (CNS) portfolio with pharmaceutical and biotechnology companies.

Suven Presentations at AAIC 2026

The company's scientific team will present data across multiple sessions covering various CNS candidates:

Presentation Title	Date	Time
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SUVN-I6107, a M1 PAM, in Healthy Human Subjects	July 12	7:30 AM - 4:15 PM
SUVN-L1101142: A Muscarinic 4 Positive Allosteric Modulator for the Treatment of Alzheimer's Disease and Schizophrenia	July 13	7:30 AM - 4:15 PM
Masupirdine (A Pure 5-HT6R Antagonist): Updates from the Phase-3 Clinical Trial Program Targeting Agitation in Alzheimer's Dementia	July 15	7:30 AM - 4:15 PM
Usmarapride, selective 5-HT4R partial agonist: an update on the clinical development program for the treatment of cognitive disorders	July 15	7:30 AM - 4:15 PM
Efficacy and Safety of SUVN-N9503012, a Selective 5-HT1A Partial Agonist for the Symptomatic Treatment of Neurodegenerative Disorders	July 15	7:30 AM - 4:15 PM

Clinical Pipeline Overview

Suven Life Sciences holds a portfolio of five clinical-stage assets focused on CNS disorders. Masupirdine (SUVN-502) is currently in a global Phase-3 study for the treatment of agitation in patients with dementia of the Alzheimer's type. Other assets include Samelisant (SUVN-G3031) for narcolepsy, Ropanicant (SUVN-911) for major depressive disorders, Usmarapride (SUVN-D4010) for cognitive disorders, and SUVN-I6107 for cognitive disorders. The company owns all intellectual property rights for its assets in all major markets.

Historical Stock Returns for Suven Life Sciences